News
-
Researchers Uncover A Viable Way For Colorectal Cancer Patients To Overcome Drug Resistance
4/10/2012
When combined with other treatments, the drug cetuximab—which works by slowing or stopping the growth of cancer cells—has been shown to extend survival in certain types of cancer, including metastatic colorectal cancers.
-
Lilly's Anti-IL-17 Monoclonal Antibody, Ixekizumab, Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis
3/29/2012
New Phase II data, published today in the New England Journal of Medicine, showed that Eli Lilly and Company's (NYSE: LLY) ixekizumab (pronounced ix" e kiz' ue mab, previously known as LY2439821), an anti-IL-17 monoclonal antibody, met its primary endpoint in patients with moderate-to-severe plaque psoriasis, with significantly more patients achieving at least a 75 percent improvement in Psoriasis Area and Severity Index (PASI) scores from baseline (PASI 75) compared with placebo at week 12.
-
Sanofi And Regeneron Report Phase 2 Data For Potential First-In-Class Lipid-Lowering PCSK9 Antibody
3/29/2012
Sanofi (EURONEXT: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that data from two Phase 2 trials with SAR236553/REGN727, an investigational, high-affinity, subcutaneously administered, fully-human antibody targeting PCSK9 (proprotein convertase subtilisin/kexin type 9), were presented at the American College of Cardiology’s (ACC) 61st Annual Scientific Meeting in Chicago.
-
Amgen's PCSK9 Inhibitor Reduced LDL Cholesterol Up To 81 Percent In Phase 1b Study
3/26/2012
Amgen (NASDAQ: AMGN) announced today positive results from a Phase 1b clinical study of AMG 145, an investigational PCSK9 inhibitor, in patients with high cholesterol who were taking statins.
-
Agilent Technologies’ Exome Target-Enrichment System To Analyze 1,500 Samples In Erasmus Genetic Population Study
3/12/2012
Agilent Technologies Inc. recently announced that Erasmus Medical Center, Rotterdam, Netherlands, has selected the Agilent SureSelect XT Human All Exon target enrichment system along with the Agilent Bravo automated liquid-handling platform as part of the Erasmus Rucphen Family study to identify genetic risk factors for some complex genetic disorders.
-
BioClinica eClinical Suite Chosen By Top Biotech Firm
2/29/2012
BioClinica, Inc., a global provider of clinical trial management solutions, recently announced that Amarin Corporation plc has chosen the eClinical suite from BioClinica to capture and manage clinical data for their Phase IIIb cardiology clinical trial, including: electronic data capture (EDC) and data management, interactive response technology (IRT/IVR/IWR), and clinical trial management (CTMS) solutions.
-
Lubiprostone Meets Primary Endpoint In Phase 3 Clinical Trial For Opioid-Induced Bowel Dysfunction (OBD)
2/3/2012
Sucampo Pharmaceuticals, Inc. (SPI) and Takeda Pharmaceuticals U.S.A., Inc. announced recently that lubiprostone met the primary endpoint in a phase 3 clinical trial for the treatment of opioid-induced bowel dysfunction (OBD) in patients with chronic, non-cancer pain, excluding those taking methadone.
-
Enlivex Completes Patient Enrollment In Its Phase I/II Clinical Trial
1/24/2012
Hadasit Bio-Holdings (TASE: HDST, OTC: HADSY) a publicly traded portfolio of biotech companies, all based on intellectual property developed and owned by Hadassah University Hospital, Israel's foremost medical research center, today announced that the recruitment of 13 patients for the Enlivex Phase I/II clinical trial has been completed.
-
Kedem Pharmaceuticals Engages A FDA Compliant Contract Formulation Development Company For The Production Of KDM-1102 Clinical Materials
1/5/2012
Kedem Pharmaceuticals Inc. (OTCBB: KDMP), a specialty pharmaceutical company with focus on sublingual drug delivery is pleased to announce that it has signed a contract with a GMP pharmaceutical FDA compliant formulation development company, Corealis Pharma, Inc. for the production of the phase I clinical supplies of KDM-1102, the Company's second lead therapeutic drug.
-
Abbott Initiates Clinical Trial To Study Drug Eluting Bioresorbable Therapy For Treatment Of Peripheral Artery Disease
12/28/2011
Abbott recently announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit drug eluting bioresorbable vascular scaffold (BVS) for the treatment of blockages in the superficial femoral arteries (SFA) and iliac arteries that have resulted in claudication (leg pain upon walking).
This website uses cookies to ensure you get the best experience on our website. Learn more